The University of Oxford confirmed this week that a potential vaccine against COVID-19, being developed with drugmaker AstraZeneca, elicits a strong immune response in the elderly.
The findings of the vaccine test were published Thursday in the medical journal The Lancet.
“This is a very important step because the big concern with any vaccine is that it doesn’t work as well in older people,” Richard Horton, editor-in-chief of The Lancet, told Bloomberg Television, calling the new data “another brick in the house. which we are trying to build for this vaccine. “
Elderly people are most at risk for severe disease if they become infected with COVID-1
Researchers from AstraZeneca and Oxford have entered a phase III trial of their potential vaccine and are testing whether it protects the elderly, people with established health conditions and more.
The results, published Thursday in The Lancet, are from Phase II studies involving 560 healthy volunteers, 160 aged between 18 and 55, 160 aged 56 to 69 and 240 over 70. The results showed that the vaccine candidate was able to cause a reaction to the virus within 14 days after the first dose, notes Bloomberg.
The findings show that it elicits a similar immune response in adults of all ages.
Oxford researchers have vowed that the results of the Phase III process should be known by Christmas, Reuters reported.
The AstraZeneca vaccine is the world leader in the COVID-19 vaccine competition. This month, however, drugmakers Pfizer and Moderna released data from vaccine studies showing more than 90 percent test efficacy.